Development of Novel Therapies for NIDDM

$1,861,338P01FY2007DKNIH

Duke University, Durham NC

Investigators

Linked publications & trials

Paper 37392148 Paper 35997012 Paper 35797133 Paper 31745452 Paper 31672442 Paper 30924572 Paper 30733403 Paper 30726738 Paper 30257218 Paper 30054343 Paper 29972782 Paper 29805089 Paper 29779826 Paper 29700070 Paper 29515039 Paper 29427295 Paper 29351478 Paper 28982973 Paper 28094011 Paper 27868234 Paper 27679559 Paper 27496880 Paper 27432878 Paper 27408778 Paper 27346353 Paper 27060982 Paper 27059949 Paper 27050511 Paper 26836042 Paper 26748706 Paper 26571396 Paper 26491014 Paper 26404723 Paper 26344103 Paper 26344101 Paper 26254576 Paper 26154055 Paper 25943328 Paper 25901039 Paper 25654596 Paper 25643703 Paper 25530493 Paper 25480291 Paper 25469992 Paper 25422356 Paper 25422105 Paper 25409152 Paper 25352600 Paper 25320331 Paper 25296331 Paper 25288790 Paper 25271624 Paper 25271296 Paper 25250633 Paper 25071025 Paper 25050734 Paper 24910426 Paper 24825877 Paper 24733433 Paper 24606092 Paper 24482226 Paper 24409338 Paper 24401236 Paper 24395925 Paper 24353177 Paper 24130332 Paper 24051248 Paper 24013159 Paper 24009397 Paper 23929677 Paper 23881193 Paper 23823480 Paper 23787216 Paper 23776431 Paper 23610059 Paper 23572519 Paper 23466304 Paper 23333571 Paper 23249694 Paper 23235149 Paper 23180883 Paper 23160531 Paper 23042849 Paper 22981137 Paper 22928974 Paper 22927473 Paper 22921456 Paper 22768837 Paper 22701716 Paper 22560225 Paper 22560213 Paper 22560212 Paper 22527599 Paper 22493093 Paper 22373529 Paper 22240810 Paper 22191650 Paper 22152305 Paper 22124715 Paper 22025712

Abstract

[unreadable] The overarching goal of this program project grant (PPG) continues to be the development of novel[unreadable] therapies for type 2 diabetes. The program has evolved from its genesis in 1999 as a collaboration[unreadable] between three research Centers within the University of Texas Southwestern Medical Center in Dallas[unreadable] (UTSWMC) to its current format, involving collaboration of four Centers located at UTSWMC and Duke[unreadable] University Medical Center. The program will continue with its unique format of melding projects on[unreadable] diabetes mechanisms with projects focused on development of new technologies for studying and[unreadable] treating the disease. In the past funding cycle, the most compelling advances have occurred in the[unreadable] area of pancreatic islet biology and related technologies. We have therefore chosen to focus the[unreadable] competitive renewal of this application on development of new strategies for understanding and[unreadable] reversing beta-cell dysfunction of type 2 diabetes. Project 1 (Newgard) will investigate novel pathways for[unreadable] control of beta-cell function and growth that have emerged in the prior funding period, particularly the role[unreadable] of the homeodomain transcription factor Nkx6.1 in the biology of normal and dysfunctional mature islet[unreadable] cells. Project 2 (Sherry) seeks to develop novel PET and MR agents for molecular imaging of islet[unreadable] beta-cells in vivo. Project 3 (Kodadek) will create cell permeable synthetic molecules capable of[unreadable] activating the expression of specific performance- or growth-enhancing genes in islet beta-cells. These[unreadable] projects will be supported by an Administrative Core (Core A), an Islet Targeting Core (Core B), which[unreadable] deploys two novel technologies for delivery of molecular cargo to islet beta-cells in living animals, and a[unreadable] Metabolomics Core (Core C), which provides state-of-the-art mass spectrometry (MS)- and nuclear[unreadable] magnetic resonance (NMR)-based technologies for comprehensive metabolic profiling and[unreadable] measurement of metabolic flux.

View original record on NIH RePORTER →